RT Journal Article
T1 Implications of ACC/AHA Versus ESC/EAS LDL-C Recommendations for Residual Risk Reduction in ASCVD: A Simulation Study From DA VINCI.
A1 Vallejo-Vaz, Antonio J
A1 Bray, Sarah
A1 Villa, Guillermo
A1 Brandts, Julia
A1 Kiru, Gaia
A1 Murphy, Jennifer
A1 Banach, Maciej
A1 De Servi, Stefano
A1 Gaita, Dan
A1 Gouni-Berthold, Ioanna
A1 Kees Hovingh, G
A1 Jozwiak, Jacek J
A1 Jukema, J Wouter
A1 Gabor Kiss, Robert
A1 Kownator, Serge
A1 Iversen, Helle K
A1 Maher, Vincent
A1 Masana, Luis
A1 Parkhomenko, Alexander
A1 Peeters, André
A1 Clifford, Piers
A1 Raslova, Katarina
A1 Siostrzonek, Peter
A1 Romeo, Stefano
A1 Tousoulis, Dimitrios
A1 Vlachopoulos, Charalambos
A1 Vrablik, Michal
A1 Catapano, Alberico L
A1 Poulter, Neil R
A1 Ray, Kausik K
A1 DA VINCI Study Investigators, 
K1 Atherosclerotic cardiovascular disease
K1 Cardiovascular disease prevention
K1 Cardiovascular risk
K1 LDL-C
K1 Lipid-lowering
K1 Statins
AB Low-density lipoprotein cholesterol (LDL-C) recommendations differ between the 2018 American College of Cardiology/American Heart Association (ACC/AHA) and 2019 European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) guidelines for patients with atherosclerotic cardiovascular disease (ASCVD) ( DA VINCI was a cross-sectional observational study of patients prescribed lipid-lowering therapy (LLT) across 18 European countries. Ten-year cardiovascular risk (CVR) was predicted among ASCVD patients receiving stabilized LLT. For patients with LDL-C ≥ 70 mg/dl, the absolute LDL-C reduction required to achieve an LDL-C of  Of the 2039 patients, 61% did not achieve LDL-C  In ASCVD patients, achieving ESC/EAS LDL-C goals could result in a 2% additional ARR over 10 years versus the ACC/AHA approach.
YR 2022
FD 2022-05-14
LK http://hdl.handle.net/10668/20496
UL http://hdl.handle.net/10668/20496
LA en
DS RISalud
RD Jun 1, 2025